Focal Segmental Glomerulosclerosis Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
TVTX | C | Travere Therapeutics, Inc. | 0.00 | |
ZVSA | F | ZyVersa Therapeutics, Inc. | -2.92 |
Related Industries: Biotechnology Drug Manufacturers - Major
Related ETFs - A few ETFs which own one or more of the above listed Focal Segmental Glomerulosclerosis stocks.
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BBP | D | BioShares Biotechnology Products Fund | 3.02 | |
LABD | D | Direxion Daily S&P Biotech Bear 3X Shares | 0.33 | |
LABU | D | Direxion Daily S&P Biotech Bull 3X Shares | 0.22 | |
XBI | D | SPDR S&P Biotech ETF | 0.2 | |
IBBQ | D | Invesco Nasdaq Biotechnology ETF | 0.11 |
Compare ETFs
- Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a histopathologic finding of scarring (sclerosis) of glomeruli and damage to renal podocytes. This process damages the filtration function of the kidney, resulting in protein loss in the urine. FSGS is a leading cause of excess protein loss—nephrotic syndrome—in children and adults. Signs and symptoms include proteinuria, water retention, and edema. Kidney failure is a common long-term complication of disease. FSGS can be classified as primary versus secondary depending on whether a particular toxic or pathologic stressor can be identified as the cause. Diagnosis is established by renal biopsy, and treatment consists of glucocorticoids and other immune-modulatory drugs. Response to therapy is variable, with a significant portion of patients progressing to end-stage kidney failure. FSGS is estimated to occur in 2-3 persons per million, with males and African peoples at higher risk .
Popular Now
Recent Comments
- LillyMilly1 on LILM
- LillyMilly1 on LILM
- TraderMike on RYDE what a RIDE!!! Holy Crap!
- Crunching_The_Market on RYDE what a RIDE!!! Holy Crap!
- LillyMilly1 on LILM
From the Blog
Featured Articles